Stockscreener 앱 받기
60.27
1.58%
0.94
시간 외 거래:
60.27
전일 마감가:
$59.33
열려 있는:
$59.89
하루 거래량:
1.63M
Relative Volume:
0.81
시가총액:
$11.65B
수익:
$3.29B
순이익/손실:
$268.74M
주가수익비율:
43.98
EPS:
1.3704
순현금흐름:
$759.12M
1주 성능:
+1.96%
1개월 성능:
+2.15%
6개월 성능:
+6.02%
1년 성능:
+2.14%
1일 변동 폭
$59.32
$60.99
1주일 범위
$57.42
$60.99
52주 변동 폭
$49.26
$66.28
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
60.27 | 11.47B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 재개 | Morgan Stanley | Overweight |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-20 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
BioMarin Partners with n-Lorem to Develop Therapy for ReNU Syndrome - Intellectia AI
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
BioMarin partners with n-Lorem to develop ReNU syndrome treatment - Investing.com
BioMarin partners with n-Lorem to develop ReNU syndrome treatment By Investing.com - Investing.com Canada
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome - PR Newswire
TradingKey - TradingKey
Biomarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Biomarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Biomarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Biomarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Biomarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
BioMarin Pharmaceutical Inc (BMRN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioMarin Pharmaceutical (NASDAQ:BMRN) Presents a High-Quality Breakout Setup with Strong Technical Ratings - ChartMill
BioMarin Pharmaceutical Inc (BMRN) Institutional Confidence - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biomarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Biomarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
BMRN|BioMarin Pharmaceutical Inc|Price:59.350|Chg%:+0.480 - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Layoff Tracker: CLINUVEL will cut up to 20% of staff, relocate HQ to New York - BioSpace
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada
BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset - Seeking Alpha
BioMarin stock trades steady as rare disease revenue grows and gene therapy outlook develops - Ad-hoc-news.de
Biotech Advances VOXZOGO Toward Landmark US FDA Approval - Streetwise Reports
BMRN5187965 Bond Profile — Key Metrics - TradingView
BioMarin Pharmaceutical Inc. (BMRN) Investor Outlook: A 47.61% Upside Opportunity In Biotech - DirectorsTalk Interviews
US9061GAK7 Bond Profile — Key Metrics - TradingView
2 Reasons to Avoid BMRN and 1 Stock to Buy Instead - Yahoo Finance
Trading Systems Reacting to (BMRN) Volatility - Stock Traders Daily
BioMarin (BMRN) Wins FDA Review For VOXZOGO Full Approval In Achondroplasia - Sahm
BMRN Maintained by Citigroup -- Price Target Raised to $76.00 - GuruFocus
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma - BioSpace
BMRN6299744 Bond Risk Profile - TradingView
H.C. Wainwright reiterates BioMarin stock rating at Neutral By Investing.com - Investing.com South Africa
BMRN6299744 Bond Profile — Key Metrics - TradingView
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo - Yahoo Finance
H.C. Wainwright reiterates BioMarin stock rating at Neutral - Investing.com
Amicus Therapeutics Reports 2025 Financial Results, Merger With BioMarin, and Key Pipeline Updates - Minichart
BioMarin SNDA seeking full Voxzogo approval accepted by FDA - MSN
BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation - Yahoo Finance
BioMarin (BMRN) details Amicus 2025 results and $14.50-per-share merger terms - Stock Titan
FDA accepts BioMarin application for full VOXZOGO approval - Investing.com UK
BioMarin seeks full approval for VOXZOGO - grafa.com
FDA accepts BioMarin application for full VOXZOGO approval By Investing.com - Investing.com Australia
BioMarin Seeks Full Approval for VOXZOGO in Achondroplasia - Intellectia AI
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia - PR Newswire
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit - AOL.com
Young people with PKU take the mic in BioMarin podcast series - Fierce Pharma
Is BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions? - Sahm
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth - TradingView
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):